Novartis data confirm rapid response and high efficacy of Cosentyx in psoriasis patients for first time in China

  • Phase III study shows close to 9/10 patients who received Cosentyx 300mg achieved clear or almost clear skin during the first 16 weeks of treatment (87%), with rapid onset of relief seen as early as week 3
     
  • Results strengthen unique position of Cosentyx as a rapid and long-lasting complete treatment of psoriatic disease, with over 200,000 patients treated worldwide
     
  • Data is being presented at the 2019 American Academy of Dermatology (AAD) Annual Meeting in Washington, D.C.

Basel, March 4, 2019 - Novartis announced today new data in 441 Chinese patients with moderate to severe plaque psoriasis from a Phase III study investigating the efficacy and safety of Cosentyx (secukinumab). The data, part of a broader ongoing 52 week Phase III study in 543 patients, show 97.7% of patients treated with Cosentyx 300mg achieved PASI 75 and 80.9% achieved PASI 90 by week 12, with 87% of patients reaching PASI 90 by week 16. In patients treated with Cosentyx 150mg, 87.8% achieved PASI 75 and 66.4% achieved PASI 90 at week 12 .

"Cosentyx continues to deliver what psoriasis patients need - reimagining care to provide clear skin and a complete treatment," said Eric Hughes, Global Development Unit Head, Immunology, Hepatology and Dermatology, and China Region Development Head. "We’re excited to report for the first time data for a Chinese population, and to see strong support from the data for Cosentyx."

Cosentyx is backed by a wealth of research with 100 studies and has been proven to offer clear or almost clear skin in 8 out of 10 patients within 16 weeks of treatment. Nearly 100% of response rates are maintained up to 5 years. It is a fully human monoclonal antibody neutralizing IL-17A and has demonstrated rapid, long-lasting efficacy and safety in the treatment of moderate to severe psoriasis, psoriatic arthritis, and the more persistent manifestations of psoriasis, namely scalp, palms, soles and nails[5,6].

About Cosentyx
Cosentyx is a targeted biologic and the first and only fully-human treatment that specifically inhibits IL-17A, a cornerstone cytokine involved in the inflammation and development of psoriatic disease, including psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS)[7-10]. IL-17A is produced by both IL-23 dependent and IL-23 independent pathways, by various cells from both the innate immune system (which can be triggered by mechanical stress) and the adaptive immune system. By acting directly on IL-17A, Cosentyx inhibits this cornerstone cytokine irrespective of where the IL-17A comes from.

Cosentyx is an established brand, supported by 5-year sustained efficacy and safety data across three indications (PsO, PsA and AS) and more than 200,000 patients treated[2,6,12,13]. Cosentyx has shown fast and sustained long-term efficacy, as well as a consistently favorable safety profile, with almost zero injection site reactions and pain[6,12,14-17]. It is approved in more than 80 countries, which includes the European Union countries and the US, and is supported by 100 studies in the real world and clinical setting[2,18].